SDC1 and Miyoshi myopathy: Many studies are investigating the use of CD138 as a suitable target for therapy as it is readily accessible on the cell membrane and it is fundamental in the physiology of malignant PCs, especially in aggressive relapsed/refractory (RR) stages of MM (Table 1).